company background image
VRCA logo

Verrica Pharmaceuticals NasdaqGM:VRCA Stock Report

Last Price

US$1.34

Market Cap

US$55.0m

7D

2.3%

1Y

-63.3%

Updated

11 Oct, 2024

Data

Company Financials +

Verrica Pharmaceuticals Inc.

NasdaqGM:VRCA Stock Report

Market Cap: US$55.0m

Verrica Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Verrica Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.34
52 Week HighUS$11.41
52 Week LowUS$1.04
Beta1.45
11 Month Change-30.57%
3 Month Change-84.27%
1 Year Change-63.29%
33 Year Change-89.97%
5 Year Change-90.85%
Change since IPO-92.34%

Recent News & Updates

The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Oct 03
The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 17
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Aug 16
With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Recent updates

The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Oct 03
The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 17
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Aug 16
With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jul 21
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jan 11
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

Jun 28
Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Feb 05
We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Vectoring Back In On Verrica Pharmaceuticals

Aug 31

Verrica Pharmaceuticals reports insider buying

Jul 06

Verrica Pharmaceuticals stock slides on proposed share offering

Jun 29

Verrica Pharmaceuticals Should Receive Second CRL Today

May 24

Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)

Mar 07
Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 06
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook

Dec 17
Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook

FDA extends review period for Verrica Pharmaceuticals' VP-102 NDA

May 28

Verrica Pharmaceuticals EPS beats by $0.32

May 07

Verrica Pharma refiles US application for lead candidate in infectious skin disease

Dec 23

Shareholder Returns

VRCAUS PharmaceuticalsUS Market
7D2.3%1.1%1.2%
1Y-63.3%18.0%31.9%

Return vs Industry: VRCA underperformed the US Pharmaceuticals industry which returned 18% over the past year.

Return vs Market: VRCA underperformed the US Market which returned 31.9% over the past year.

Price Volatility

Is VRCA's price volatile compared to industry and market?
VRCA volatility
VRCA Average Weekly Movement18.0%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.4%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: VRCA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VRCA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013100Ted Whitewww.verrica.com

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial.

Verrica Pharmaceuticals Inc. Fundamentals Summary

How do Verrica Pharmaceuticals's earnings and revenue compare to its market cap?
VRCA fundamental statistics
Market capUS$55.04m
Earnings (TTM)-US$86.93m
Revenue (TTM)US$13.91m

4.1x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VRCA income statement (TTM)
RevenueUS$13.91m
Cost of RevenueUS$22.32m
Gross Profit-US$8.41m
Other ExpensesUS$78.52m
Earnings-US$86.93m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.04
Gross Margin-60.48%
Net Profit Margin-625.06%
Debt/Equity Ratio-321.4%

How did VRCA perform over the long term?

See historical performance and comparison